Grifols SA

Grifols SA is a global healthcare company specializing in the development, manufacture, and distribution of plasma-derived therapies and related medical products. The company organizes its core business into segments covering biopharmaceuticals, diagnostics, and biological supplies. Its offerings include specialized therapeutic plasma derivatives, transfusion medicine systems, diagnostic instruments, and biological materials for healthcare applications. Grifols delivers these essential treatments and medical products primarily to hospitals, clinical laboratories, healthcare providers, and patients worldwide requiring critical plasma therapies.

The enterprise operates across an international footprint that includes dedicated operations and facilities across North America, the European Union, and other global regions. It maintains a widespread operational network supported by specialized subsidiary entities located in countries such as Spain, the United States, Canada, Germany, and Egypt. Grifols SA conducts its business globally and maintains its corporate headquarters in Spain.

Summary of the business section of Grifols's latest annual report, written by StockData.

“Our sales, marketing and distribution network included 1,613 employees as of December 31, 2025, which included 1,419 sales and distribution personnel and 194 marketing employees.”